Abgent was built to complete the Genome Omniscient Antibody Library

Abgent is a biological reagents and custom services company located in Oxfordshire with its parent company headquartered in San Diego. Our G.O.A.L. is:

The Genome Omniscient Antibody Library: not just a tongue twister, Abgent’s acronym denotes our core strategic objective which is to support groundbreaking scientific research by developing an antibody against every protein in the human proteome.

Whilst achieving our G.O.A.L., our standard is to provide:

• High Quality, Low Cost: Abgent develops all our research products in-house to provide high quality, low cost products and services to support groundbreaking scientific research across the globe.
• Communication: Abgent assigns a project co-ordinator for every custom project we undertake to keep you fully informed at all stages.
• Speed: We make sure that you get your products as soon as possible so your critical experiments are not delayed.

Abgent has two core strengths to its business: our catalogue products and our custom services.

Catalogue Products:
Abgent’s catalogue products can be classified in the following categories: Autophagy, Apoptosis, Stem Cells, Phosphorylation, Cell Function & Gene Regulation research. Having moved into a world class production facility Abgent can now develop more than 3,000 antibodies a year – more than any other firm globally. This allows us to develop antibodies for use against the hottest molecules in the latest research.

Custom Services:
Abgent takes pride in the standard and the range of our custom services. We are able to offer Antibody Development including monoclonal, polyclonal and rabbit monoclonal antibodies; Peptide Synthesis where we are able to synthesise long and difficult peptides at a low cost; and, Protein Expression in mammalian bacterial and baculoviral systems. High-quality, rapid turnaround & personal support is guaranteed and by consulting with you at critical project junctures we ensure optimum product provision.

Contact us at [email protected] or go to our website at www.abgent.com

Alacrita provides expertise-based consulting services to the biotechnology, pharmaceutical and healthcare industries. Unlike many consulting firms, all of Alacrita’s consultants are considered experts in their particular field after spending a significant portion of their careers in industry.

Alacrita conducts two types of consulting. The first is embedding a consultant within a client’s management team to fill a specific gap in expertise. The client tends to be a biotech company operating a virtual or semi-virtual model and the area of expertise may be preclinical development, clinical development, manufacturing or regulatory affairs.

The second is assembling multi-disciplinary teams to execute specific consulting projects. Such projects span a range of activities but are generally centred around either a strategic or analytical theme. Real life examples range from advising a government on implementing a streamlined biotech regulatory framework through to crafting drug development plans to underpin a financing event.

Alacrita’s continued engagement with hands-on drug development allows us to deliver project-based consulting that is rooted in the real world. Without coal-face experience, such exercises become theoretical and struggle to be translated into industrial reality.

Almac is a financially stable, privately owned organisation with over 30 years experience. The Group provides integrated development solutions to over 600 customers worldwide including all the world leaders in the pharmaceutical and biotechnology sectors.
The company has over 2,800 employees and is headquartered in Craigavon, Northern Ireland; US operations are based in Pennsylvania, North Carolina and California. Each customer is guaranteed a dedicated hands-on project management service to meet individual needs ensuring clients will experience continued success in all their ventures.
Almac provides a seamless, fast and efficient route from drug discovery through to market. Our range of services includes:

Research: Almac is focused on the delivery of biomarker solutions and supporting biomarker strategy for drug development, which underpins the delivery of personalised medicine.
Chemical & Pharmaceutical Development: Almac accelerates the development of customers’ drug candidates through the effective integration of science and manufacturing to provide drug substance & product.
Clinical Development: Almac is unique in the industry, offering fully integrated world class clinical trial supplies & IVR/IWR technology.
Commercial: Almac provides solid dosage form commercial manufacture and packaging for EU & US markets. Commercial support services facilitate EU market access for non-EU product.

Exhibiting at Booth 56

Alpha Biologics provides process development and contract manufacturing services for recombinant proteins and monoclonal antibodies. Our experts manage the full range of process development and scale-up activities using laboratories in Cambridge, UK or Penang, Malaysia. Services include cell line generation, stability and optimisation studies, cell banking, upstream & downstream process development, scale-up and cGMP manufacture. Final production takes place at our purpose-designed, FDA / EMEA cGMP compliant manufacturing facility in Penang, Malaysia. This is a cutting-edge design, with flexible internal lay-out and a bioreactor range of 10 to 500 litres - and enables us to deliver fast-track, low-cost protein manufacture for R&D, pre-clinical, clinical trial or final market uses. Project examples include mammalian cell line growth studies, the production of antibodies and Fab fragments, the development of human fibroblast growth parameters, mammalian cell supernatant production, cell membrane preparation from recombinant cell lines, serum-free hybridoma productivity evaluations, and many other applications.

Established in 1989, the BIA (BioIndustry Association) exists to encourage and promote a financially sound and thriving bioscience sector within the UK economy and concentrates its efforts on emerging enterprise and the related interests of companies with whom such enterprise trades. With over 250 members, the BIA supports a wide range of sectors, majoring on the human health benefits of the technology and represents the interests of these innovative companies to a broad section of stakeholders from patient groups to politicians, advancing its members interests both within the UK and internationally to create a healthy UK bioscience sector which benefits society.

BioPark, the ‘Outer London’ science park offers life science businesses high quality start-up and grow-on space combined with comprehensive business support. The chemistry and biology laboratories are well equipped with fume hoods and microbiological safety cabinets. Additionally dark rooms, autoclaves and freezer rooms are provided on site. There is also an ‘open access’ biomarker lab for use by researchers.
BioPark covers around 9,000 square meters and offers a range of laboratory configurations in floor areas from 30 to 180 square metres - ideal for biotechnology, diagnostics and medtech research and development. Most laboratories have write-up areas and associated offices. Together with 24/7 security, BioPark also provides meeting conference and event facilities, including a 66-seat lecture theatre, for use by tenants and others.
Owned by and close to the University of Hertfordshire, the science park is ideally situated for national and international travel, being just 40 minutes from central London by train and having good road access to three London airports.
BioPark provides exceptional networking and collaboration opportunities as it sits at the centre of the Cambridge-Oxford-London research ‘golden triangle’, within which are located key clinical research centres, Universities, pharmaceutical multinationals and over 400 biotechnology companies.

BioPartner.co.uk is an accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Sciences organisations across the UK. Operating both independently and in partnership with the UK government, BioPartner assists SMEs to exhibit overseas, and supports start-ups through the BiotechNet team of consultants. At BIO-Europe we co-ordinate the UK Pavilion. in partnership with UK Trade & Investment.

cddi is an international biotechnology and pharmaceutical consulting company, led by a full time core management team of senior people who have developed more than 30 products globally from discovery to market. Our Managing Partners personally direct a global network of people that cover a wide range of drug development expertise with skills to operate in all project areas. Since formation, we have worked with both large pharma and small biotechs, as well as with investment companies.
cddi’s Managing Partners and our people focus on operational management as well as strategic direction. Unlike a traditional consultancy who talk and advise, our mode of working is hands-on and delivery focused. With our extensive industry experience and the expertise of our people, we will achieve your specific objectives faster and more cost-effectively.

CDSS provides flexible, competitive, high quality clinical trial management, research nurse and site management organisation services throughout the UK and Europe to international pharmaceutical, medical device and biotechnology industries.
We are a clinical research organisation (CRO) working in Phase I to IV clinical trials with a wealth of experience in numerous therapeutic areas, especially oncology, cardiovascular, pain and dermatology.
Having worked with clients ranging from small start-up biotechnology companies to large multinational pharmaceutical companies & the NHS, CDSS recognises the individual requirements of our clients and can provide a service tailored to your individual needs.
Our services include Contract Research Nursing (we are the UK’s leading independent research nurse provider), Project Management, Monitoring and Clinical Trial Administration.
Whether you want Research Nurses, Study Site Coordinators or Clinical Research Associates (CRAs), we have the skills and staff to meet your requirements on a full or part time basis.

Cellzome is a privately-owned drug discovery and development company, and a leader in the use of chemical proteomics technologies to identify a new generation of selective drug candidates for the treatment of inflammatory and other important diseases. Our pipeline of small-molecule therapeutics is driven by Kinobeads™ and Episphere™ proprietary technologies for screening and profiling kinases and epigenetic targets in their physiological context. Our goal is to identify oral therapeutics for inflammatory diseases and to leverage our Kinobeads™ and Episphere™ platforms in all indications through partnerships with pharmaceutical companies. Cellzome has already established significant kinase and epigenetics collaborations with GSK in immuno-inflammation.

Cizzle Biotech is a spin out company from the University of York, founded around the work of Dr Dawn Coverley and colleagues. Product development is focussed on the CIZ1 gene and its potential as a diagnostic marker and therapeutic target for a variety of cancers.
The Company is supported by funds primarily from the White Rose Seed Fund, Yorkshire Cancer Research and the Viking Fund.
Cizzle’s mission is the creation of value through the development of world leading science into innovative diagnostic and therapeutic products in partnership with the biotech and pharma industries. Its first focus is lung cancer.
Cizzle Biotechnology is a Medilink member

CrystecPharma applies the latest supercritical fluid technologies to improve the design and performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical and biopharmaceutical industries, contributing to human health by enabling new and more effective therapies. Crystec supercritical fluid technologies can be applied to both small drug molecules and biotechnologically sourced drugs.
Our services include crystal form screening and particle design, addressing issues of poor solubility and stability, improved delivery, and product enhancement in support of lifecycle management. We are also engaged in in-house programmes to develop improved small and large molecule therapeutic products.
The CrystecPharma team consists of the some of the world’s leading scientists in the field of supercritical fluid technology-based pharmaceutics, including Professor Peter York. The first product manufactured using this technology is planned to launch next year.
Our technology and extensive knowhow enable us to provide the following product solutions:
- Crystal and particle engineering for targeted delivery and enhanced product performance
- Stabilisation and rapid reconstitution of molecules derived from biotechnology
- Formation of pure metastable forms that have enhanced solubility and which demonstrate enhanced physical and chemical stability
- Improved inhaled and nasal delivery through optimised particle design
Crystec is a Medilink member

Cyprotex Discovery Limited is the world’s largest contract research organisation specialising in preclinical ADMET services to research scientists engaged in drug discovery and development. We provide support for a wide range of experimental and computational ADMET and PK services extending from early drug discovery through to IND submission.

Cyprotex core capabilities include our unique high throughput ADME screening service which is based on state of the art robotics and a highly sophisticated customised information management system. This dramatically reduces the cost and time involved in generating data whilst ensuring excellent reproducibility of data. Our customised experimental service provides support for later stage ADME and Pharmacokinetic studies specific to customer requirements. Our in silico ADME predictive modeling service provides a range of novel predictive technologies. Cyprotex’s proprietary software product Cloe® PK integrates core ADME and physicochemical properties to predict whole body pharmacokinetics and is available on our secure web portal, Cloe® Gateway. Toxicity is the key reason for drug attrition. Our in vitro toxicology service assists customers in understanding the toxic liabilities of their compounds using a panel of different techniques and helps identify which compounds have the optimal ADME and safety profile to advance into the clinic.

Eagle Genomics Ltd. is a leading bioinformatics software company based in Cambridge UK at the heart of Europe’s largest Biotech cluster. Eagle bridges the gap between academia and industry by providing packaged, ready-to-use state-of-the art, open bioinformatics for genomic data management and integration. It can also augment the capability and capacity of existing Bioinformatics departments by providing outsourced services.
Eagle’s global clients include multinational Pharmaceutical organisations as well as Biotech SMEs to which they provide installation, customisation, integration, support and training services for a range of open-source bioinformatics tools and databases, including Ensembl®, Taverna."

Eden Biodesign is a globally-integrated biopharmaceutical and vaccine contract manufacturing company offering strategic consultancy, biopharmaceutical design and cGMP manufacturing services.

We have a long history of successfully completed commercial assignments, for clients in Europe, North America, Asia, Africa, Australasia and Latin America. Our client base ranges from biotech start ups to the world’s largest and most respected multinational biopharmaceutical companies.

Eden Biodesign operates a world-class facility in Liverpool, UK that provides a full range of services for biopharmaceuticals and vaccines, including: cell line/strain development and banking, process development, cGMP manufacturing and analytical development for all significant biopharmaceutical product technologies - mammalian, microbial and viral.

Epistem is a biotechnology company commercialising its expertise in epithelial stem cells in the areas of oncology, gastrointestinal diseases and dermatology. Epistem’s Contract Research Division has a track record of providing bespoke preclinical efficacy testing services to over 130 international clients in biotechnology, pharmaceutical and personal care sectors.

Through specialist knowledge of epithelial diseases, the scientists at Epistem have developed a range of unique in vitro and in vivo assay methodologies which can be used to assess the mode of action and efficacy of new drug candidates. With expertise in disorders of intestinal, breast, skin and oral epithelia, Epistem screens new compounds to assess their potential as anti-cancer agents, IBD agents, mucositis modulatory agents, cell cycle stimulators or inhibitors and wound healing regulators. Novel services that Epistem has recently introduced into its research service portfolio include an adoptive T-cell transfer IBD model, in vitro and in vivo cancer stem cell and angiogenesis assays and a unique plucked hair follicle cancer biomarker platform.

Dr Peter Grant, Operations Director
Peter gained a Ph.D in Biochemistry from Cardiff University before embarking on his career in industry. He held research and development positions in Genzyme and Celltech before joining Enzymatix in 1988, his first start-up. He became head of R&D for Enzymatix and then a co-founder and director of Celsis in 1992, a spin-out from Enzymatix where he eventually became Director of Business Development and Technology on the Board of directors. During his time at Celsis, Peter was a member of the management and presentation team that floated Celsis on the LSE in 1993. Peter left Celsis in 2002 and co-founded Biofusion plc, listing this on the AIM in 2005.
Biofusion has since been renamed FusionIP and has exclusive agreements with Sheffield and Cardiff Universities to exploit University owned intellectual property. Peter’s role as Operations Director is to take an active position in the founding and development of Fusion portfolio companies, normally as Chairman/NED, and to head the Pipeline team that manages and evaluates the Fusion Pipeline of projects generated by the two Universities.
Fusion IP is a Medilink member

GMD has developed a revolutionary molecular separation platform that is based on a disposable microfluidic chip. The chips are application specific and allow for high throughput, ultra-sensitive analysis of biomarkers, protein expression and DNA sequencing up to unprecedented read lengths.
Compared to conventional ubiquitous separation technology, our system has shown increase in detection sensitivity by two orders of magnitude, increase in peak capacity by a factor of 300 and increase in throughput that can reach three to four orders of magnitude.
GMD intends to use the chip as a genetic test to accompany personalised drugs and as a biomarker based diagnostic tool to assist drug discovery.
GMD is looking for a partner/end user to out license its technology and at the same time develop its product portfolio driven by the specific needs of the end user.
GMD is based in the National Physical Laboratory, one of the top research facilities in the UK. The company was awarded a exceptional R&D grant from the London Development Agency to bring its technology to market.

Unique drug lead-finding opportunities through screening the MycoDiverse™ natural products library of basidiomycete metabolites, from fermentations of tropical and temperate mushroom species.

• Producer of high quality natural products libraries for proprietary and collaborative drug lead compound discovery.
• Chemical novelty greater than 50%
• Reproducible, proprietary fermentation of mushroom fungi (basidiomycetes)
• Many compounds chemically tractable
• Strong early stage proprietary oncology pipeline, led by fully synthetic chemical series with mTOR/CDC25 inhibition
• Discovery of patentable molecules via collaboration from only four months after screening Hypha's MycoDiverse chemical library

• Expert (fee for service) provider of contract services
• Compound purification/identification
• Antitumour cell cytotoxicity/antiproliferative bioassays
• Antibacterial and antifungal bioassays
• Fermentation services (low molecular weight compound production/purification)

ICON Development Solutions has conducted clinical pharmacology studies in Manchester for over 25 years and we are experienced in:

• clinical pharmacology
• regulatory affairs
• pharmacokinetics
• pharmacodynamics
• pharmacometrics
• biopharmaceutics
• bioanalysis

This summer we relocated our clinical pharmacology unit to our purpose-built facility within the Central Manchester University Hospitals Foundation Trust (CMFT) campus in Manchester. The two-floor, 34-bed hospital-based unit includes a sample handling laboratory, 24-hour medical cover, local GMP pharmacy, contiguous access to the Accident and Emergency department at the Manchester Royal Infirmary and importantly is located just 1 mile from our bioanalytical facilities. The unit also features four fully environmentally controlled pharmacodynamic testing suites where ICON continues its industry-leading work modelling complex pathologies to identify early efficacy signals of compounds in clinical areas such as Neuropathic Pain, Anxiety and Cognitive Degeneration.

Our state of the art bioanalytical facilities support the 3 streams of bioanalysis (small molecule, macromolecule PK & immunogenicity and biomarker analysis) to high scientific standards which is demonstrated through our long standing relationships with our clients. We routinely work with clients on their bioanalytical and immunoassay programmes from late phase discovery through to Phase IV.

Our services are underpinned by sound regulatory, scientific and medical advice based on many years undertaking programmes of drug and medical device development.

ICT Biosciences is the business arm of the Institute of Cancer Therapeutics at the University of Bradford. Through the Institute we provide advanced research services and offer problem solving expertise in cancer drug discovery and development. With over 30 years experience, a team of academic and technical staff and modern facilities, we offer expertise in:

• Drug design & synthesis
• Drug target characterisation
• In vitro evaluation
• In vivo evaluation
• Drug metabolism and pharmacokinetics
• PK & PD modelling
• Early clinical trials & GCLP clinical trial support
• Provision of human tissue

ICT Biosciences and the Institute of Cancer Therapeutics work with a range of academic and industrial partners throughout the world both on a collaborative research and a fee for service basis. The Institute has research collaborations based in UK, Europe, USA and China. On a commercial basis ICT Biosciences works with academic groups, pharmaceutical and biotechnology companies around the world, including UK, Europe, USA, Australia/New Zealand.

IPI offers contract services in formulation design and development from drug discovery support through to prototype clinical and commercial formulation for both small molecule and biopharmaceutical therapeutics; including access to a range of standard and proprietary technologies and expertise including particle size reduction, amorphisation, co-crystallisation and super critical fluid crystallisation. IPI has expertise over a range of dosage forms with services supported by a team of formulation and analytical scientists and a wide range of sophisticated analytical equipment.
Services include-

• Designing and developing new formulations across a range of dosage forms
• Feasibility studies and design of inhaled therapeutic formulations
• Providing a range of technologies and expertise focused on enhancing dissolution of poorly soluble API’s
• Developing analytical methods for measuring the physical characteristics and purity of raw materials and pharmaceutical products
• Preformulation package including salt and polymorph screening
• Commercial formulation problem solving involving a range of analytical techniques

Technologies

• Particle size reduction- nano-particle technologies
• Crystal engineering-Super Critical Fluid technologies
• Amorphisation- Melt extrusion technologies
• Co-crystallisation- Melt extrusion technologies
• Extended release technology

Biologics Service Offerings includes

• Protein characterisation- a range of analytical instruments available
• A focus on protein aggregation analysis
• Formulation design, stability and stress testing and process troubleshooting

Isogenica specialises in providing protein engineering and molecular evolution services using its core technology, “CIS display”, to pharmaceutical and biotechnology companies for the rapid discovery, identification and design of new peptide polypeptide and antibody lead compounds.
CIS display can quickly construct polypeptide libraries of unprecedented size and complexity in vitro, without the need for cloning. A library of up to a hundred trillion different clones can be easily generated in a few hours and quickly processed so that better products and motifs can be selected in just a few days. CIS display technology has provided hits and information against a wide range of targets and has advantages over alternative technologies.
The technology is adaptable for the display of different proteins and licences are available for scFv and other polypeptide scaffolds. Isogenica has secured more than a dozen partnering and licensing deals to date and is seeking further collaborations with companies actively engaged in developing peptide and polypeptide systems.

Medella Therapeutics is a company focused on the discovery and development of novel drugs that interfere with the cell signalling activities of Receptor Activity Modifying Proteins or ‘RAMPs’. RAMPs are exciting targets implicated in a range of diseases including bone disease, cancer, cardiovascular disease, inflammation, neurological function and obesity. Medella’s initial focus is on cancer, using monoclonal antibodies to modulate cell signalling by targeting specific RAMPs that are predominantly associated with tumour cells. The company has established a proprietary position around this technology and has data from in vitro and in vivo (model) studies to support the selectivity for tumour cells and potential to act via several mechanisms of action. Medella is seeking potential partners interested in oncology, including companies seeking access to targets for proprietary antibody engineering technology.
Medella Therapeutics is a Medilink member

Medilink (Yorkshire & Humber) Ltd is a private company which represents Life Science businesses in the UK region of Yorkshire & Humber, and through the Medilink UK network, life science businesses across the UK.

Medilink offer specialist consultancy services, including international partnering (technology exchange, joint intellectual property & technology licensing), joint venturing, international product placement, PR and marketing, and UK market access (including clinical trials & clinical engagement).

We are keen to meet with similar representative organisations that would be interested in developing partnerships in the UK. We would also like to hear from life science companies that may benefit from our services, particularly companies which may have a single technology and would gain value from partnering with UK companies with complementary technologies, or which would be interested in collaborating in product development.

Moredun Scientific is a GLP/ GMP accredited contract research organization providing research and testing services to the animal health, pharmaceutical and biotechnology industries supporting the development, registration and manufacture of veterinary and human medicines.

Areas of work include:

• Animal Health Contract Research Services: Efficacy and safety studies in livestock for a broad range of veterinary medicinal products. Feed additive studies, antimicrobial pharmacodynamics, and analytical pharmacology. Extensive, flexible animal facilities ranging from high containment to open fields are available.
• Biosafety Testing Services: In vivo assays for the detection of viral contaminants. Tumorigenicity studies. Microbiology services including tests for sterility, mycoplasma and mycobacteria. All tests are conducted to meet international regulatory guidelines.
• Biological Materials: Custom preparation of a range of biological materials including antisera, viruses, bacteria and other material for research or commercial use.
• Collaborative Research: Veterinary medicinal product development, in conjunction with the Moredun Research Institute.

OET Ltd is a biotechnology company and centre of excellence for baculovirus based recombinant protein expression. OET provides protein expression products, services, consultancy and training to pharmaceutical and biotech companies and academic institutions. OET is also carrying out an extensive R & D programme.

O2h is a 5 year old discovery services company with project offices in Cambridge UK and research campus in Ahmedabad, India. The Indian operations provide a high level of chemistry expertise while UK office provides project management support.
Current clients of O2h include several top 20 pharmaceutical and biotechnology companies in the US, Europe and Japan. O2h adheres to the highest standards of performance with a particular emphasis on rapid interactive communications and delivery speed.
Services provided by O2h include FTE-based synthetic chemistry, medicinal chemistry, computational chemistry, full services lab-units and ADME.
Since April 1, 2009, O2h has gone live at its new, 10,000 sq m research facility, which has capacity for 28 dedicated 12 FH lab units. Aside from its core chemistry strengths, O2h have also been enhancing its in-house ADME capability. More information about Biology is available at http://o2h.com/InvitroADME.asp. The business (people, process and infrastructure) has been built to provide a tier one service for managing FTE collaborations.

Penn services include:
CMC Consultancy, Formulation Development, Analytical Development, Clinical Trial Supply, Contract Manufacturing, Qualified Persons Release Services, Paediatrics Formulation and Manufacturing, Hi-Potency capabilities, Orphan drug expertise, More than 30 Years of specials, manufacturing expertise, Comparator Sourcing.
The above offerings are all under one roof providing a strong and easy communication channel between departments making developments, manufacturing and analytical processes.

Pharmidex was created in in 2002 to provide unique expertise to clients who were developing medicines for CNS diseases. Over the last few years Pharmidex has established itself as the world leading centre for studying the CNS distribution and biochemical effect of new drugs using its proprietary NeuroPK and NeuroPD technologies.
Today Pharmidex provides an extensive range of in vivo and in vitro ADMET/PK and acute and chronic safety support expertise to underpin its world leading position in CNS expertise. Existing platform technologies or bespoke studies to address client specific needs are rapidly undertaken by highly qualified scientists with academic and industry backgrounds.

Piramal Healthcare provides a wide range of API and drug product manufacturing, development and packaging services to meet clinical trial and commercial needs.
Working with companies from top 20 pharma to small virtual pharma, Piramal supply product and services to all major pharmaceutical markets. We manufacture and package Phase I – III clinical trials materials through to commercial volumes for API and solid dosage drug product. Approval by the MHRA of our clinical trials packaging and distribution offering means that we can offer clients with products in development, a full service offering from one location.
We have built a reputation for offering an excellent manufacturing capability and extremely efficient operating systems that deliver outstanding quality. Combined with our uncompromisingly professional attitude and uniquely flexible approach to meet deadlines, Piramal Healthcare endeavours to provide the solution to your out sourcing requirement.

ProImmune is your ideal strategic partner for managing the immunogenicity risk of biological drugs, the discovery of new antigens, e.g. for targeted sub-unit vaccines, and monitoring immune responses, such as cellular and humoral immune responses, with the most advanced technologies.
Whether you are looking to improve the specificity of your therapy, reduce unwanted immunogenicity or simply broaden your IP portfolio, ProImmune can provide all or any part of the solution.

ProPharma Partners is a global biopharm consultancy able to assist clients with commercial, preclinical, clinical and regulatory needs.
ProPharma Partners provides a broad and extensive range of business development expertise including strategy and partnering, pre-clinical and clinical development management services, regulatory assistance, due diligence assessment, valuations and early stage financing advice.
ProPharma Partners is present in the three major pharmaceutical markets Europe, Japan and USA. Areas of therapeutic expertise include oncology, immunology, inflammation, pain, CNS, metabolic diseases, cardiovascular disorders, anti-infectives, respiratory diseases and dermatology.
ProPharma Partners employs a proven and successful multidisciplinary team approach working closely with clients to quickly and efficiently assist clients in achieving their business goals and initiatives. Specific activities in which ProPharma Partners have established proven track records and successes include:

• Facilitating corporate partnering between biopharmaceutical companies
• Identifying and acquiring technologies, products or companies
• Designing, developing and implementing preclinical and clinical development plans to support licensing approval
• Developing and implementing business plans
• Providing interim business development management for early stage biopharmaceutical companies
• Assessing and valuing technologies, intellectual property and therapeutic products
• Assisting in early stage financing

Randox Pharma Services offers a comprehensive range of technologies and solutions, allowing Pharma R&D and clinical trials to become more efficient, cost effective and safer.
Our award-winning Biochip Array Technology enables multiple biomarker results from a single sample and the Rx Series of clinical chemistry analysers, Quality Control sera, Diagnostic Reagents, Life Science products and Custom Assay Development service offers the highest quality and most comprehensive biomarker and companion diagnostic development package available.

Retrogenix is a biotechnology company based in Sheffield, UK. Founded by Dr Jim Freeth (ex-AstraZeneca) and Jo Soden (ex-Manchester University), the company has developed a world-leading Cell Microarray technology that is used to rapidly determine which proteins are targeted by small molecule and large molecule (antibody, protein and peptide-based) drug candidates or marketed drugs.
Retrogenix’s technology is ideally suited to deconvoluting the primary targets of drug molecules with desired functional activity. In addition, by identifying secondary drug targets, its technology can be used to reduce the incidence of drug-induced toxicities and/or to uncover new disease opportunities for existing drugs.
The company has developed screens, in human cells, against a large proportion of the human proteome, comprising of all target classes. In addition, screens against specific sub-sets of the human proteome have been developed. This includes the most comprehensive panel of human membrane proteins, a key target class for both small molecule and protein/antibody-based drugs.
By providing access to its powerful technology, Retrogenix allows its drug discovery/pharmaceutical partners to improve success rates and to generate maximum return on their R&D investments.
Retrogenix is a Medilink member

Sareum is a drug discovery company focused on producing targeted small molecule therapeutics to address unmet medical needs, primarily in cancer. The Company aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum has a portfolio of discovery-stage, targeted small molecule programmes which it would like to discuss with potential licence and/or collaborative partners.

Sareum Holdings plc joined the AIM market of the London Stock Exchange in October 2004, trading under the symbol SAR.

SELCIA DISCOVERY offers integrated drug discovery services from hit identification to candidate selection, including screening biology, medicinal chemistry, ADME/PK and in vivo PK work.

Our expertise in capillary electrophoresis (CE) offers our clients the benefits of a powerful and proven technology applied to drug discovery screening on a wide variety of targets. CE is a high-resolution separation technique able to detect both high and low affinity molecular interactions. Our proprietary fragment screening, CEfrag™ is a highly effective application of this powerful technology.

SELCIA is also a leader in 14C radiolabeling providing radiolabelled compounds for preclinical and clinical ADME studies including GMP radiolabelled API.

We are based at a 2,500 m2 modern facility with GLP analytical laboratory, in Ongar, Essex (UK)

UKTI is the government organisation that helps UK-based companies succeed in the global economy. Its range of expert services is tailored to the needs of individual businesses to maximise their international success. It provides companies with knowledge, advice and practical support.
UKTI also helps overseas companies bring high quality investment to the UK’s economy – acknowledged as Europe’s best place from which to succeed in global business. It provides support and advice to investors at all stages of their business decision-making.
UKTI offers expertise and contacts through a network of international specialists across the English regions and in British embassies and other diplomatic posts around the world.
The UK Trade & Investment Enquiry Service is the main point of contact for customers. The team handles trade and inward investment enquiries received via +44 (0) 20 7215 8000, by e-mail through the “Contact Us” service on the www.ukti.gov.uk website and [email protected], and by mail/fax.

Vitrology is a GLP/ GMP accredited contract testing organization providing testing services to the pharmaceutical and biotechnology industries and to the veterinary industry supporting the development, registration and manufacture of veterinary and human medicines. We have a broad range of assays to allow GMP testing from Cell banks to Virus Seeds until Bulk harvest and final pure biological drug substance.
Areas of work include:

• In vitro and in vivo adventitious virus assays
• Retrovirus testing by PCR and infectivity assays
• Electron Microscopy - TEM, Viral particle quantification in bulk harvest.
• Molecular Biology assays - Residual host cell DNA, RT assays (FPERT and QPERT), Species specific virus detection by qPCR,Identity , purity and stability assays.
• Tumorigenicity testing of cell lines
• Custom assay development and validation.
• Assay Development/validation and transfer to client`s facilities.
• Regulatory and scientific consultancy support

www.vitrologybiotech.com

Warwick Effect Polymers (WEP) specialises in novel technologies to enhance biological therapeutics. WEP’s two proprietary biopolymer technologies are GlycoPol™ for drug targeting and delivery and PolyPEG® for extending the half-life of biologics. The Company’s objective is to develop partnerships with third parties to produce GlycoPol™ and PolyPEG® enhanced therapeutics and to license-out the technologies for specific molecules and/or applications.

GlycoPol™ is based on glycopolymers containing a diverse array of carbohydrates that offers the potential to target biological therapeutics, including proteins, peptides and oligonucleotides, to carbohydrate receptors on specific cells and tissues for cell uptake. PolyPEG® is a next generation PEGylation technology based on comb-shaped, PEG-containing polymers that not only have very low viscosity, allowing high concentrations to be administered to patients without difficulty, but also do not cause the tissue accumulation associated with conventional PEGs.